Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mushroom extract shows promise against stubborn HPV

NCT ID NCT06752083

Disease control Sponsor: Liaquat University of Medical & Health Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a supplement made from shiitake mushrooms (AHCC) can help women clear a long-lasting high-risk HPV infection. Researchers reviewed medical records of 289 women who either took the supplement, got the HPV vaccine, or did both. The goal was to see if the virus became undetectable after 4 to 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

289 people

The number who actually took part.

Started

Jan 2023

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women with documented persistent high-risk HPV infection for at least six months whose clinical data were retrospectively identified from medical records at multiple participating gynecology centers.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female participants aged 18 years or older. * Documented persistent high-risk HPV infection for at least 6 continuous months, confirmed by consecutive HPV-DNA tests. * Absence of high-grade cervical lesions (≤ CIN1). * Availability of complete clinical records with evaluable HPV-DNA testing at baseline and follow-up. * Documented management with AHCC® supplementation alone, nonavalent HPV vaccination alone, or combined AHCC® supplementation and nonavalent HPV vaccination in routine clinical practice. * No prior excisional or ablative treatment of the cervix (including conization or LEEP). Exclusion Criteria: * History of cervical excisional or ablative treatment (including conization or LEEP). * Presence of high-grade cervical lesions (CIN2 or worse) or invasive cervical cancer. * Incomplete clinical documentation or missing HPV follow-up data. * Conditions known to significantly alter immune function, including ongoing immunosuppressive therapy, active autoimmune disease requiring systemic treatment, or documented immunodeficiency, when such information was available in medical records. * Prior systemic antiviral or immunomodulatory therapy specifically aimed at HPV clearance during the observation period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HPV infection

Contacts and locations

Locations

  • University of Insubria

    Varese, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.